Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 204(6): 2227-2232, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38504552
ABSTRACT
Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dexametasona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Bortezomib
/
Lenalidomida
/
Anticorpos Monoclonais
/
Mieloma Múltiplo
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article